News Details

allosteric modulators for human health

stock datapress releasescorporate eventsdownloads
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking


- Data reinforces broad therapeutic potential of oral ADX71441 

- Program on track for CTA filing before end of 2012

Geneva, Switzerland, 29 October 2012 – (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today positive preclinical data for its GABA-B receptor positive allosteric modulator (PAM) oral small molecule, ADX71441, in a validated rodent model of alcohol binge drinking. ADX71441 demonstrated robust, dose-dependent and long-lasting suppression of alcohol intake in animals compared to naltrexone, the most-commonly prescribed treatment of alcoholism on the market.

“These data are extremely encouraging and superior to naltrexone in our pre-clinical model, and warrant further exploration as a novel treatment for alcoholism,” said Professor Klaus Miczek at Tufts University (USA) in whose laboratory the study was performed.

Both clinical and pre-clinical data suggest that activation of the GABA-B receptor offers a unique therapeutic opportunity to address largely unmet needs of patients with alcohol and drug abuse by (1) reducing the alcohol or drug intake; (2) alleviating many physical signs (pain, Gastrointestinal/urinary disturbances) and emotional symptoms (anxiety) associated with withdrawal; and (3) maintaining abstinence by reducing alcohol or drug craving.

ADX71441, which has potential for once daily dosing and selectively activates the GABA-B receptor, was evaluated in a mouse model of alcohol binge drinking. Acute, oral administration of ADX71441 (3, 10, 30 mg/kg) resulted in a dose-dependent suppression of alcohol intake, achieving 80% reductions at higher doses (10, 30 mg/kg) in comparison to vehicle treatment. Reductions in alcohol consumption in response to ADX71441 treatment were present for the entire 4hour alcohol access period. The effect of ADX71441 in this model was more robust and longer-lasting than that seen in mice treated with naltrexone, which was used in the study as a positive control. This is the first study showing efficacy of a GABA-B receptor PAM in a rodent model of alcohol binge drinking.

“Alcoholism is an important unmet medical need as current treatments offer marginal efficacy in reducing alcohol intake and are associated with significant side effects,” noted Dr. Graham Dixon, CSO at Addex. “We are excited by the robustness of the data and look forward to the filing of a CTA for ADX71441 by the end of 2012 and initiating Phase 1 testing in Q1 2013.”

Oral small molecule GABA-B receptor PAMs have potential in treating multiple indications and Addex has previously demonstrated positive proof of concept in a broad range of preclinical models, including those of pain, anxiety, obsessive-compulsive disorder and overactive bladder (OAB). Addex is positioning ADX71441 as a treatment for spasticity, with multiple sclerosis (MS) being an initial focus of the clinical development program.

“The advancement of ADX71441 towards the clinic clearly illustrates our strategy to bring forward innovative oral small molecule NCEs addressing validated targets with broad therapeutic potential,” said Bharatt Chowrira, CEO at Addex. “GABA-B receptor is one such exciting target whose activation has been validated in a broad range of indications. We plan to initially focus on evaluating ADX71441 for the treatment of spasticity in MS patients who currently are not adequately treated for this debilitating disease.” 

About Alcoholism

Alcoholism is a broad term for problems with alcohol, and is generally indicative of compulsive and uncontrolled consumption of alcoholic beverages. It is medically considered a disease, specifically an addictive illness. The World Health Organization estimates that about 140 million people throughout the world suffer from alcohol dependence. Patients with alcoholism suffer major changes to the brain structure and chemistry. Excessive alcohol consumption damages almost every organ in the body and the cumulative toxic effects can cause both medical (cirrhosis of the liver, pancreatitis, heart disease, peptic ulcers, sexual dysfunction) and psychiatric (epilepsy, dementia, psychosis, anxiety & depression) problems. Treatment of alcoholism is complex with current standard of care typically being prescribed to patients with heavy drinking but largely being unable to prevent them from relapsing.   

About GABA-B Receptor Activation

Activation of gamma-aminobutyric acid subtype B receptor (GABABR), a Family C class of GPCR, is clinically and commercially validated by a generic GABA-BR agonist, baclofen, which is marketed for spasticity in spinal cord injury patients. Baclofen has also shown clinical relevance in a number of other indications including overactive bladder, pain and is in early stage clinical development for alcohol dependence and autism. Despite baclofen’s broad clinical validation, it is not commonly used due to multiple side effects, rapid clearance, development of tolerance to the drug, rebound and withdrawal syndromes. Orthosteric GABA-BR agonists have also shown clinical validation in gastroesophageal reflux disease (GERD). Addex’ GABA-BR PAMs have shown efficacy in multiple preclinical models including: OAB, pain, osteoarthritis pain, anxiety and alcoholism.

Addex Therapeutics (www.addextherapeutics.com) discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company's two lead products are being investigated in Phase 2 clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia and anxiety seen in patients suffering from major depressive disorder. Addex also is advancing several preclinical programs including: GABA-BR PAM for spasticity in MS, OAB and other disorders; mGluR4 PAM for Parkinson's, MS, anxiety and other diseases. In addition, Addex is applying its proprietary discovery platform to identify highly selective and potent allosteric modulators of a number of both GPCR and non-GPCR targets that are implicated in diseases of significant unmet medical need.

Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
PR@addextherapeutics.com

Disclaimer: The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGluR2, mGluR4, mGluR5, GABA-BR or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABA-BR or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABA-BR or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABA-BR or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.


Geneva, Switzerland, 27 July 2016 – Addex Therapeutics (SIX: ADXN) announced today that ADX71441, a positive allosteric modulator (PAM) of the GABAB receptor...

LifeSci Capital Issues Equity Research Report on Addex Therapeutics

 

Geneva, Switzerland, 20 July 2016 – Addex Therapeutics (SIX: ADXN), announced today that the independent life science research...

Addex Shareholders Approved all Board Proposals at 2016 Annual General Meeting


Geneva, Switzerland, 24 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of directors...

Addex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction


Geneva, Switzerland, 9 June 2016 – Addex Therapeutics (SIX: ADXN), announced today positive results with ADX71441, a GABAB receptor positive allosteric...

Van Leeuwenhoeck Issues Research Note on Addex Therapeutics


Geneva, Switzerland, 8 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that the independent life science research company Van Leeuwenhoeck has...

Addex Annual General Meeting Scheduled for 23 June 2016


Geneva, Switzerland  2 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 23 June 2016, at 11:00am at the...

Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society


Geneva, Switzerland, 2 June 2016 – Addex Therapeutics (SIX: ADXN) announced today that results from its Phase 2 clinical study of dipraglurant in...

Addex Increases Issued Share Capital and Creates Treasury Shares

 

Geneva, Switzerland, 30 May 2016 – Addex Therapeutics (SIX: ADXN) announced today that it has increased its capital from...

Addex Therapeutics Reports 2015 Financial Results

Geneva, Switzerland, 29 April 2016 – Addex Therapeutics (SIX: ADXN) announced today 2015 financial results.


2015 Financial Highlights...

Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

 

Geneva, Switzerland, 11 April 2016 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers


Geneva, Switzerland, 15 March 2016 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

 

Additional analysis underlines the potential significant therapeutic benefit of dipraglurant to patients with Parkinson’s disease....

Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease


FDA Orphan Drug Status Validates the Potential Therapeutic Use of Dipraglurant in this Rare Disease

Geneva,...

Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial


Geneva, Switzerland, 17 December 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents


Geneva, Switzerland, 15 December 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis


Geneva, Switzerland, December 9, 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex Moves R&D Operations to Geneva’s Campus Biotech


Geneva, Switzerland, December 7, 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program


Geneva, Switzerland, 25 November 2015
– Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases


Geneva, Switzerland, 23 November 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share


Geneva, Switzerland, 19 November 2015
– Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder


Successful collaboration with the US National Institute for Alcohol Abuse and Alcoholism

Geneva, Switzerland, 13 October 2015 – Addex Therapeutics...

Addex Therapeutics Reports First Half 2015 Financial Results

Geneva, Switzerland, 30 September 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy


Geneva, Switzerland, 23 September 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field


  • Addex Grants Option to License mGlu3 Receptor Program to Pierre Fabre Pharmaceuticals
  • Pierre Fabre Pharmaceuticals will conduct chemistry, pharmacology and ADME*

<p...

Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics


Geneva, Switzerland, 17 August 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease

 

Geneva, Switzerland 14 August 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

valuationLAB Issues Research Report on Addex Therapeutics


Geneva, Switzerland, 5 August 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

 

Geneva, Switzerland, 22 July 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based...

Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting

Geneva, Switzerland, 12 June 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced...

Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain

 

Geneva, Switzerland 3 June 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia

 

5th Biennial Workshop on Dystonia “Controversies in Dystonia and Parkinsonism” Rome, 29-30 May 2015

Geneva, Switzerland 29 May 2015 – Addex Therapeutics (SIX: ADXN), a leading company...

Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia

 

Geneva, Switzerland 7 May 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a...

Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017

 

Geneva, Switzerland, 9 March 2015 – Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF2.8 million in a private placement of new issued registered...

Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation

Geneva, Switzerland, 23 February 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug...

Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death

 

Geneva, Switzerland, 19 February 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that...

Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update

 

Geneva, Switzerland, 9 January 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today:

Financial Update<br...

Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder


Geneva, Switzerland, 7 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today...

Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000

 

Geneva, Switzerland, 17 December 2014 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has received USD757,000...

Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder

 

Geneva, Switzerland, 21 October 2014 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a...

Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction


ADX71441 reversed somatic signs of withdrawal in nicotine-dependent mice and reversed hyperalgesia, further supporting the use of GABA-B activation as a strategy to achieve smoking cessation

Geneva, Switzerland, 10...

Addex Shareholders Approve All Board Proposals at Annual General Meeting

 

Geneva, Switzerland, 30 June 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved all...

Addex Therapeutics Publishes Annual General Meeting Agenda

Geneva, Switzerland, 12 June 2014 - Addex Therapeutics (SIX:...

Addex Therapeutics Publishes Annual Report 2013

 

Geneva, Switzerland, 30 May 2014 - Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual Report 2013 in accordance with the notice given in the press release of 30 April...

Addex Therapeutics Reports 2013 Financial Results

 

2013 Financial Highlights

  • Significant reduction in 2013 cash utilization of CHF12.3 million, significantly below guidance of CHF15 million, CHF1.6 million used in second half of 2013...

Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

 

Geneva, Switzerland, 7 February 2014 - (SIX:ADXN), Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced today top-line data from a Phase 2a...

Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

 

Geneva, Switzerland, 4 November 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the...

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

On track to report top line results end of Q1 2014

Geneva, Switzerland, 29 October 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development...

Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

Geneva, Switzerland, 3 October 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that ADX71441 dose...

Addex Therapeutics First Half 2013 Financial Results

 

Geneva, Switzerland, 17 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today its first...

Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

 

Geneva, Switzerland, 4 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today additional...

Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors

Cash runway extended to end of 2014

Geneva, Switzerland, 9 August 2013 – Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.2 million (US$3.5 million) in a private placement...

Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down

                             
Geneva, Switzerland, 31 May...

Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders


Company intends to restructure the organization and monetize its pipeline and platform assets

Geneva, Switzerland, 28 May 2013 – Addex Therapeutics (SIX: ADXN), announced today that it...

Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

  • ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinical model
  • The data confirms the role of gamma-aminobutyric acid (GABA) in modulating GH plasma concentrations...

Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study

 

• Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in non-human primate model of Parkinson’s Disease levodopa-induced dyskinesia
• Data reinforces Phase 2a pharmacological...

Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role

 

Geneva, Switzerland, 30 April 2013 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Co-Founder and Chief...

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence


• Data reinforces broad therapeutic potential of ADX71441, an oral GABAB receptor Positive Allosteric Modulator
• Recent approval of Clinical Trial Application (CTA)  to initiate a Phase 1, first–in-man,...

Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441


ADX71441, a novel oral small molecule GABA-B receptor positive allosteric modulator, on track to initiate clinical testing in first half of 2013 and to deliver top-line safety, PK and biomarker data by year...

Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare dystonias

Geneva, Switzerland, 22 April 2013 – Addex Therapeutics (SIX:ADXN),...

Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

Dipraglurant, an mGlu5 negative allosteric modulator, currently in Phase 2 studies for levodopa-induced dyskinesia is on track for start of Phase 2 studies in rare dystonias in the first half of...

Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)

$1 MM grant by The Michael J. Fox Foundation to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia

Geneva,...

Addex Shareholders Approve All Board Proposals at Annual General Meeting

Geneva, Switzerland, 20 March 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its...

Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

Grant to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia

<link...

Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor

Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs by integrating proprietary functional and structural biology...

Addex to Focus Resources on Clinical Pipeline

 

2013 Value Drivers:

• Initiate Phase 2 clinical testing of dipraglurant (mGlu5 NAM) in a rare disease indication
• Submit Orphan Drug Application in U.S. and Europe for dipraglurant<br...

Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia


Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase 2 clinical testing in the second half of 2013

 

Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441

ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half of 2013

Allostery: Key to addressing important unmet needs in CNS diseases

Addex'high throughput allosteric drug discovery platform is paving the way for a new approach to cracking "undruggable" therapeutic targets.

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking

- Data reinforces broad therapeutic potential of oral ADX71441 

-

Dyskinesia: Hope on the Horizon

YouTube

Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases


Grant to Further Characterize Allosteric Modulators Against mGluR4 and mGluR7
Geneva, Switzerland, 2 October 2012

Addex...

Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model

A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis
Geneva, Switzerland, 24 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering...

Soutien américain au biotech à Genève

ADDEX.Le titre a bénéficié d'un regain d'intérêt des investisseurs outre-Atlantique.
La direction plaide encore la sous-évalutation.

Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms

Geneva, Switzerland, 17 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug...

Addex Therapeutics First Half 2012 Financial results

Geneva, Switzerland, 22 August 2012 – Addex Therapeutics...

Positive Early Results for Addex Parkinson's Drug Dipraglurant Spur Hopes for Deal


In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa.

Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models


- Seminal Research Provides Greater Insight into the Role of Selective mGluR4 Modulation on Motor Symptoms 

Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder

  • Program on track for IND filing before end of 2012
  • GABA-BR PAM compounds have potential in several major Indications

Geneva,...